What is the significance of the upcoming data presentation for dupilumab?

The presentation of Phase 2a trial data for dupilumab at the ATS International Conference is significant because it will provide early clinical insights into the drug's efficacy and safety profile for treating moderate-to-severe asthma. Positive results could validate the drug's potential and support further development, impacting investor confidence and Regeneron's future valuation.

When and where will the dupilumab Phase 2a data be presented?

The data from the Phase 2a trial of dupilumab is scheduled to be presented on May 21, 2013, at the American Thoracic Society (ATS) International Conference, held in Philadelphia, Pennsylvania. The presentation will occur during the Late Breaking Abstracts in Clinical Trials Session at 9:00 AM EDT.

What does the "Late Breaking Abstracts" designation imply?

The designation "Late Breaking Abstracts" typically means that the presented data represents significant and recent findings that were not available in time for earlier abstract submission deadlines. This often indicates that the results are noteworthy and potentially impactful, generating anticipation among conference attendees and the scientific community.

REGN 8-K: Regulation FD

Q: What is dupilumab and how does it work?

Dupilumab (also known as REGN668/SAR231893) is an investigational, high-affinity, subcutaneously administered, fully human monoclonal antibody. It targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha), a key component in the signaling pathways of interleukins 4 and 13, which are involved in inflammatory responses, particularly in allergic diseases.

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report (8-K) on April 2, 2013, to disclose upcoming presentation of data from a Phase 2a clinical trial for its investigational drug, dupilumab (REGN668/SAR231893). Dupilumab is a fully human monoclonal antibody designed to target the alpha subunit of the interleukin 4 receptor (IL-4R alpha) and is being studied for the treatment of moderate-to-severe asthma. Investors can anticipate key efficacy and safety findings from this trial to be presented at the American Thoracic Society (ATS) International Conference in Philadelphia. The presentation is scheduled for May 21, 2013, during the Late Breaking Abstracts in Clinical Trials Session. This disclosure provides an early look at potential clinical outcomes for a promising pipeline candidate, which could significantly influence the company's future growth prospects.

Key Highlights

1Regeneron to present Phase 2a trial data for dupilumab (REGN668/SAR231893) for moderate-to-severe asthma.
2Dupilumab is a fully human monoclonal antibody targeting the IL-4R alpha pathway.
3Data presentation scheduled for May 21, 2013, at the ATS International Conference.
4The presentation will be part of the Late Breaking Abstracts in Clinical Trials Session.
5This event offers an early insight into the clinical performance of a key pipeline drug candidate.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Apr 2, 2013)

Summary

Key Highlights

Frequently Asked Questions